Skip to main content

Table 2 Clinical outcome of S-1 treatment for refractory thymic carcinoma

From: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

Clinical outcome N° of patients (n = 14)
Response to chemotherapy N (%) 95 % CI
 Complete response 0 (0 %)  
 Partial response 6 (42.9 %) [21.4–67.4]
 Stable disease 6 (42.9 %) [21.4–67.4]
Progression disease 2 (14.3 %) [0.04–39.9]
Median response duration, moths [95 % CI] 8.1 [2.6–12.2]
Median overall survival, months [95 % CI] 30.0 [6.2–41.9]
1-year survival rate, % 68.8  
  1. CI confidence interval